Eribulina Zentiva

Eribulin Mesylate is a chemotherapy drug used to treat certain types of cancer. It works by slowing or stopping cancer cell growth, often prescribed for metastatic breast cancer.

Eribulin Mesylate is primarily used in the treatment of advanced breast cancer that has spread to other parts of the body. It is administered intravenously and is designed to target and destroy cancer cells. This medication is often considered when other treatments have not been effective. Patients should consult their healthcare provider to understand the specific uses of Eribulin Mesylate for their condition.

Common effects of Eribulin Mesylate may include fatigue, nausea, and hair loss. Some patients may experience fever, constipation, or peripheral neuropathy. These effects can vary in severity and duration. It is important to discuss any persistent or severe side effects with a healthcare professional.

Eribulin Mesylate should be handled with care and administered by a healthcare professional. It is important to follow all safety guidelines and precautions provided by the manufacturer and healthcare provider. Patients should inform their healthcare provider about any allergies or medical conditions before starting treatment.

Eribulin Mesylate may interact with other medications, including those that affect liver function or blood cell production. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain foods may also affect the efficacy of Eribulin Mesylate.